$4.7 billion broadside for J&J over talc cancer claims

13 July 2018
medical_legal_law_big

After many years of litigation from cancer patients, a court in Missouri, USA, has ordered healthcare giant Johnson & Johnson (NYSE: JNJ) to pay an eye-watering $4.7 billion in damages to 22 women who allege harm caused by products containing talc.

Naturally-occurring talc can contain asbestos, a known carcinogen, whereas the talc used in cosmetics such as baby powder does not.

While there is incomplete clinical evidence concerning the impact of products containing talc, a US Food and Drug Administration study found no traces of asbestos in a range of products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical